%PDF-1.4
%
33 0 obj
<>
endobj
30 0 obj
<>
endobj
88 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-03-05T15:09:57Z
2024-03-28T18:51:13-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-28T18:51:13-07:00
application/pdf
Heather
2002-934.omeract.april
uuid:29e68802-1dd2-11b2-0a00-020927bd7200
uuid:29e68804-1dd2-11b2-0a00-880000000000
endstream
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
34 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
106 0 obj
[110 0 R]
endobj
107 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
420 777 137 -27 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:4)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(872)Tj
ET
0 0 0 0 scn
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 scn
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 72 714.5293 Tm
[(J. Rheumatology outcomes: the patient\325)54.8 (s perspective. J Rheumatol)]TJ
0 Tc 0 Tw 0 -1.25 TD
(2003;30;880-3.)Tj
-0.00011 Tc 0.02499 Tw -1.3 -1.25 Td
[(4.)-550.1 (Kirwan JR. Minimum clinically important dif)17.7 (ference: the crock of)]TJ
1.3 -1.25 Td
(gold at the end of the rainbow? J Rheumatol 2001;28:439-44.)Tj
-1.3 -1.25 Td
[(5.)-550.1 (T)35 (ugwell P)110.7 (, Boers M, for the OMERACT)-257.3 (Committee. Developing)]TJ
1.3 -1.25 Td
[(consensus on preliminary ef)17.7 (ficacy endpoints for RA)-220.2 (clinical trials. )]TJ
T*
(J Rheumatol 1993;20:555-6.)Tj
-1.3 -1.25 Td
[(6.)-550.1 (Boers M, )17.7 (T)35 (ugwell P)110.7 (, Felson DT)73.9 (, et al. )17.7 (W)79.9 (orld Health Or)17.7 (ganization)]TJ
1.3 -1.25 Td
[(and International League of )54.8 (Associations for Rheumatology core)]TJ
T*
(endpoints for symptom modifying antirheumatic drugs in rheuma-)Tj
T*
(toid arthritis clinical trials. J Rheumatol 1994;21 Suppl 41:86-9.)Tj
-1.3 -1.25 Td
[(7.)-550.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )17.7 (The )54.8 (American College of)]TJ
1.3 -1.25 Td
(Rheumatology preliminary core set of disease activity measures for)Tj
T*
[(rheumatoid arthritis clinical trials. )17.7 (The Committee on Outcome)]TJ
T*
[(Measures in Rheumatoid )54.8 (Arthritis Clinical )17.7 (T)35 (rials. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1993;36:729-40.)Tj
-0.00011 Tc 0.0249 Tw 31.7 18.75 Td
[(8.)-550.1 (Boers M, Brooks P)110.7 (, Strand CV)128.8 (, )17.6 (T)35 (ugwell P)110.7 (.)-0.1 ( )17.6 (The OMERACT)-257.3 (filter for)]TJ
1.3 -1.25 Td
[(outcome measures in rheumatology)64.8 (. J Rheumatol 1998;25:198-9.)]TJ
-1.3 -1.25 Td
[(9.)-550.1 (van der Heijde DM, van`t Hof MA, van Riel PL, et al. Judging)]TJ
1.3 -1.25 Td
(disease activity in clinical practice in rheumatoid arthritis: first ste\
p)Tj
T*
[(in the development of a disease activity score. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1990;49:916-20.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(10.)-550.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )54.8 (American College of)]TJ
1.8 -1.25 Td
(Rheumatology preliminary definition of improvement in rheumatoid)Tj
T*
[(arthritis. )54.8 (Arthritis Rheum 1995;38:727-35)]TJ
-1.7631 -1.25 Td
[(1)36.8 (1)-0.1 (.)-550.1 (Hewlett S. Patients and clinicians have dif)17.7 (ferent perspectives on)]TJ
1.7631 -1.25 Td
(outcomes in arthritis. J Rheumatol 2003;30:877-9.)Tj
-1.8 -1.25 Td
[(12.)-550.1 (Quest E. Patients\325)-201.1 (perspective. J Rheumatol 2003;30:884-5.)]TJ
ET
0 0 0 0 scn
408 770 150 -25 re
f*
BT
0 0 0 1 scn
/T1_2 1 Tf
0 Tw 20.37 0 0 21 461.9631 753.6089 Tm
(\002\003\003\002\004\005\006\007\004#)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
36 0 obj
<>
endobj
49 0 obj
<>
endobj
38 0 obj
<>
endobj
77 0 obj
<>
endobj
93 0 obj
<>
endobj
41 0 obj
<>
endobj
43 0 obj
<>
endobj
39 0 obj
<>stream
H\n0~
S%9C~
$iie(yrv ѐ\s>,>)^x5:6G>ѐ3ح/SÇ>6[^<ܼq}oxI=1/'˲q5ִy?&Ws%tB